2 March 2023 - PDUFA date is 21 June 2023. ...
23 February 2023 - BLA supported by two pivotal trials demonstrating non-inferior vision gains to Eylea (aflibercept) Injection, with vast majority ...
21 February 2023 - US FDA has set an action date for August 2023. ...
21 February 2023 - If approved, pozelimab would be the first and only treatment for those living with CHAPLE. ...
20 February 2023 - Azafaros today announced its progress in on-going interactions with health authorities regarding its lead asset, AZ-3102. ...
20 February 2023 - Valneva today announced that the US FDA has completed a filing review of its biologics license ...
17 February 2023 - FDA also accepts a separate supplemental application to extend prophylaxis with Prevymis to 200 days in ...
16 February 2023 - PDUFA goal date is 19 August 2023. ...
14 February 2023 - ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhoea ...
12 February 2023 - IASO Biotherapeutics today announced that the US FDA has granted both regenerative medicine advanced therapy designation ...
9 February 2023 - Mesoblast today announced that the US FDA's Office of Tissues and Advanced Therapies has granted regenerative ...
7 February 2023 - Rocket Pharmaceuticals today announced that the US FDA has granted regenerative medicine advanced therapy designation to ...
6 February 2023 - Zuranolone is being evaluated as a potential 14 day, rapid acting, once daily, oral medication to treat ...
31 January 2023 - FLAG Therapeutics announced today that FLAG-003, an investigational small molecule therapy for the treatment of diffuse intrinsic ...
26 January 2023 - DiscGenics today announced the US FDA granted regenerative medicine advanced therapy designation to injectable disc cell ...